WillItSurvive
Pharma and healthcare groups · subsidiary of Otsuka Holdings Co., Ltd. (TSE: 4578) · Japan

Otsuka Pharmaceutical

otsuka.co.jp ↗

Japanese pharma maker of psychiatric drugs like Abilify and IV fluids, plus nutraceuticals.

Hard to displace
Assessed 24 July 2026 · Evidence as of 24 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 24 July 2026 · Checkable from August 12, 2026 · Every call on the record Checkpoint: Otsuka Holdings FY2026 Q2 earnings release
The call

Otsuka keeps record profits rolling in from psychiatric and nephrology drugs while patent cliffs and new pipeline bets play out in parallel.

Otsuka Pharmaceutical makes prescription drugs, especially for mental health and brain disorders, and operates its own factories across 69 sites worldwide. It is hard to replace because the company holds approved drugs, patents that block copies for years, and deep relationships with doctors, plus owning the factories themselves, but these advantages expire when patents run out, which is coming soon. The company is testing new drugs like sibeprenlimab for kidney disease and centanafadine for ADHD; if at least one or two of these new drugs win approval and sell well over the next two years, profit decline from expiring patents will be offset, but if they fail or launch slowly, the company will face a serious earnings drop.

Why
01
AI pressure: AI-driven drug discovery labs (e.g. Recursion, Isomorphic Labs). AI speeds molecule screening industry-wide but has not replaced Otsuka's regulatory filings or manufacturing scale yet. Could AI do the core job? Unlikely.
02
Bigger players: Generic drugmakers (Teva, Sandoz) post patent expiry. Loss of exclusivity on US products like Jynarque and Samsca is set to cut FY2026 profit even as new drugs ramp up. Could a giant copy it? No, they are blocked.
03
What protects it. Patent life, 69+ owned manufacturing sites, decades of psychiatrist relationships, and FDA approvals that AI cannot skip.
What would change this call
VOYXACT (sibeprenlimab) FDA approval decision for IgA nephropathy. Shows whether pipeline refill offsets upcoming loss-of-exclusivity revenue decline.
Centanafadine ADHD NDA outcome at FDA following late-2025 filing. Shows whether a second pipeline asset launches to diversify revenue post-patent-expiry.
FY2026 full-year profit versus FY2025 record ¥446.1B business profit. Shows actual scale of loss-of-exclusivity erosion versus company guidance.
Key numbers
  • Group revenue ¥2,468.9B, +6.0% YoY (2025-12-31)
  • $700M Transcend Therapeutics deal closed (2026-06-12)
  • VOYXACT Phase 3 positive two-year data (2026-07-01)
Named risks
  • FY2026 profit decline guided due to loss-of-exclusivity on major US products. Severity: high
  • Pipeline dependency: Phase 3 setbacks in VOYXACT, centanafadine, or TSND-201 could offset acquisition costs. Severity: medium
  • Nature Made turmeric supplement class action filed 2026-05-29 in Northern District of California. Severity: medium
  • Ongoing generic patent litigation (Lupin) despite favorable 2026-05-21 ruling signals continued cliff pressure. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Takeda PharmaceuticalcontestingLarger Big Five Japanese pharma peer with broader global reach as of 2025-06
Vera TherapeuticscontestingCompetes in IgA nephropathy against Otsuka's VOYXACT, positive Phase 3 data 2026-07
Vertex PharmaceuticalscontestingRival kidney-disease drug developer noted alongside VOYXACT readout, 2026-06-04
Pfizergaining onPfizer struck AI antibody-design deal with Chai Discovery, disclosed 2026-06-04, ahead of Otsuka on frontier AI tie-ups
AbbViecontestingVraylar competes with Otsuka's Abilify/Rexulti in antipsychotic market
Johnson & JohnsoncontestingRisperdal competes in same CNS antipsychotic segment as Otsuka's franchise
Questions people ask
Is Otsuka Pharmaceutical profitable in 2025?
Yes. Otsuka Holdings, its parent, reported record FY2025 group revenue of ¥2,468.9 billion (+6.0% YoY) and record business profit of ¥446.1 billion (+3.6% YoY), as of December 31, 2025.
Who owns Otsuka Pharmaceutical?
Otsuka Pharmaceutical Co., Ltd. is a wholly owned operating subsidiary of publicly traded Otsuka Holdings Co., Ltd. (TSE: 4578), which IPO'd December 15, 2010 for $2.4 billion, then the largest pharma IPO ever.
Could AI replace Otsuka Pharmaceutical's drug business?
No. AI mainly speeds early discovery via Otsuka's Schrödinger collaboration (started January 2023), but approved-drug patents, FDA designations, and 69+ owned manufacturing sites remain regulatory moats AI cannot substitute.
Is Otsuka Pharmaceutical doing layoffs?
No broad layoffs are reported. Otsuka Pharmaceutical Co., Ltd. had 6,070 employees as of December 31, 2025, and group-wide headcount was 35,338 in FY2024, reflecting steady growth rather than cuts.
Who is Otsuka Pharmaceutical's biggest competitor?
Takeda Pharmaceutical is Otsuka's largest Japanese peer among the country's Big Five pharma firms; in nephrology, Vera Therapeutics and Vertex compete against Otsuka's VOYXACT, which posted positive Phase 3 data in July 2026.
Is Otsuka Pharmaceutical facing a patent cliff?
Yes. Otsuka Holdings' FY2026 guidance, issued June 28, 2026, signals a profit decline versus FY2025 due to loss-of-exclusivity on major US products plus higher R&D spending, even as pipeline assets like TSND-201 aim to offset the impact.
Timeline
  • 2026-07-22VOYXACT Phase 3 IgA nephropathy positive data disclosed; Astex-Genentech breast cancer collaboration announced
  • 2026-06-12Otsuka completes $700M acquisition of Transcend Therapeutics for PTSD asset TSND-201
  • 2026-05-21Otsuka v. Lupin tolvaptan patent ruling affirms non-infringement, invalidity
  • 2026-04-27FY2026 Q1 results: revenue +8.2% YoY to ¥630.3B, net profit +15.7%
  • 2026-04-01TSND-201 receives FDA Commissioner's National Priority Voucher
  • 2026-03-27Transcend Therapeutics acquisition announced
  • 2026-02-12FY2025 full year results: record group revenue ¥2,468.9B, business profit ¥446.1B
  • 2025-12-31Centanafadine ADHD NDA submitted to FDA
  • 2025-10-30Licensed 4D-150 gene therapy for Asia-Pacific from 4D Molecular Therapeutics, $85M upfront
  • 2025-07-01TSND-201 receives FDA Breakthrough Therapy designation
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources